02257 SIRNAOMICS-B
- 7.000
- +0.120+1.74%
SIRNAOMICS-B News
聖諾醫藥-B：2023年度報告
Zhitong Hong Kong Stock Short Position Statement Statistics|April 26
Zhitong Hong Kong Stock Short Position Statement | April 26
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment
Sirnaomics (HKG:2257) received guidance from the US Food and Drug Administration for the drugmaker's phase 2/3 and phase 3 clinical studies of STP705 for treating squamous cell carcinoma in situ. The
Cash flow is about to run out, and Shengnuo Pharmaceutical-B (02257) is surging only to “trick people”?
The stock price dropped 90% within a year, and the majority shareholders were forced to close their positions last month. At this juncture, the stock price suddenly surged more than 20%, which is probably not a good thing for Shengnuo Pharmaceutical-B (02257). On April 17, Shengnuo Pharmaceutical's stock price opened higher in early trading, reaching a maximum increase of 37.87%. According to the news, Shengnuo Pharmaceutical announced on the same day that the company has obtained a written response from the US FDA's Class C meeting on the requirements of its core product STP705. The company has initiated the required preclinical studies in accordance with FDA guidance recommendations. According to the Zhitong Finance App, the purpose of the Class C conference mentioned above was to obtain F
Shengnuo Pharmaceutical-B (02257): Further development of STP705 for sirnaomics to treat squamous cell carcinoma in situ obtained specific guidance from the FDA
Shengnuo Pharmaceutical-B (02257) issued an announcement. The company has obtained information from the US Food and Drug Administration (FDA)...
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) fell more than 11% in the afternoon to a record low. The company's cash flow is urgent, and no products have been commercialized
The Zhitong Finance App learned that Shengnuo Pharmaceutical-B (02257) fell more than 11% in the afternoon to a new low. Recently, the stock price has continued to decline, with the biggest drop of more than 93% from its all-time high. As of press release, it fell 11.07% to HK$6.43, with a turnover of HK$16.9093 million. According to the news, Shengnuo Pharmaceutical's 2023 financial report shows that the company obtained additional revenue of US$1,414,000 during the period, a year-on-year decrease of 33.11%; shareholders should have accounted for a loss of US$786.91 million, a decrease of 10.88% year-on-year. Furthermore, according to Wind data, the company's cash and cash equivalents ranged from 2
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) fell nearly 5%, directors' salary increases raised questions in the market, and the company's cash flow was urgent
Shengnuo Pharmaceutical-B (02257) fell nearly 5%. As of press release, it was down 4.79% to HK$7.55, with a turnover of HK$4.724,200.
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) rose more than 8% in early trading, CEO says there will be no risk of forced sale of the shares held
The Zhitong Finance App learned that Shengnuo Pharmaceutical-B (02257) rose more than 8% in early trading. As of press release, it had risen 6.22% to HK$8.54, with a turnover of HK$8.3984 million. According to the news, Lu Yang, founder and CEO of Shengnuo Pharmaceuticals, said in an investor conference call in response to investors' questions that his shares will no longer be at risk of being forcibly sold. Shengnuo Pharmaceutical previously announced that the 1,560,000 company shares held by Lu Yang, accounting for 1.78% of the total number of issued shares, were forcibly sold on March 7, 2024. In addition, Shengnuo Pharmaceuticals recently announced annual results for the group's period
Sirnaomics Announces 2023 Full Year Results
Focus on integrating resources into leading development projects to promote clinical research on the core products STP705, STP707 and STP122G Hong Kong, Germany City, Maryland, and Suzhou, China, March 28, 2024/PRNewswire/ -- Sirnaomics Ltd. (the “Company”, together with its subsidiaries, collectively referred to as “SirnaOmics” or the “Group”; stock code: 2257), an industry-leading biopharmaceutical company focused on developing and creating RNAi drugs, announced the year ended December 31, 2023 Review of (“this year”)
Shengnuo Pharmaceutical-B (02257) announced annual results, loss attributable to shareholders of US$786.91 million narrowed 10.88% year-on-year
Shengnuo Pharmaceutical-B (02257) announced its annual results for the year ended December 31, 2023. The group...
SIRNAOMICS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) has risen sharply by more than 30% since listing, the company's stock price has continued to reach a new low. Recently, the two major shareholders have been forced to close their positions on
The Zhitong Finance App learned that Shengnuo Pharmaceutical-B (02257) rose sharply by more than 30% and rose 31.31% at press time to HK$10.4, with a turnover of HK$61.7 million. According to the news, the company previously announced on March 18 that approximately 99,500 company shares beneficially owned by executive director Dai Xiaochang, accounting for 0.11% of the total number of shares issued on the announcement date (held in securities accounts with secured financing in financial institutions) were forcibly sold on March 15 because they were not satisfied after issuing a deposit supplement. According to reports, after the shares were forcibly sold this time, Dai Xiaochang still owns Shengnuo Medical
Shengnuo Pharmaceutical-B (02257.HK) will hold a board meeting on March 27 to approve the annual results
On March 13, GLONGHUI | Shengnuo Pharmaceutical-B (02257.HK) announced that the company will hold a board meeting on March 27, 2024 to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
SIRNAOMICS-B: NOTICE OF BOARD MEETING
siRNAomics will present the latest developments in its dual-targeted GalNAc mRNA project at the 2024 OPT Summit
Hong Kong, Germantown, Maryland, and Suzhou, China, March 12, 2024 /PRNewswire/ -- Sirnaomics Ltd. (“Company”, stock code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), an industry-leading biopharmaceutical company focused on exploring and developing RNAi therapies. Sirnaomics announced today that it will be invited to attend the 2024 OPT Summit (Oligonucleotide and mRNA Therapy Summit) and share the company's dual-targeted innovation MUR based on GalNAC-RNAi therapy
Sirnaomics Chairman Disposes of Shares
Sirnaomics (HKG:2257) Chairman Yang Lu's 1,560,000 shares in the company were sold as part of a forced sale for failure to attain the issued margin call, according to a Friday filing with the Hong Kon
Lu Yang, executive director of Shengnuo Pharmaceutical-B, was forced to sell 1.56 million shares of the company
Shengnuo Pharmaceutical-B (02257) issued an announcement. The board of directors of the company was informed by Lu Yang, the executive director and chairman of the board that 1.56 million company shares beneficially owned by Dr. Lu, accounting for 1.78% of the total number of shares issued on the date of this announcement (stored in a securities trading account with guaranteed finance) were forcibly sold on March 7, 2024 because the security deposit requirement was not satisfied after issuing a deposit supplement.
Lu Yang, executive director of Shengnuo Pharmaceutical-B (02257), was forced to sell 1.56 million shares of the company
Zhitong Finance App News, Shengnuo Pharmaceutical-B (02257) issued an announcement. The board of directors of the company was informed by Lu Yang, the executive director and chairman of the board that 1.56 million company shares beneficially owned by Dr. Lu, accounting for 1.78% of the total number of shares issued on the date of this announcement (held in a securities trading account with guaranteed financing) were forcibly sold on March 7, 2024 because the security deposit requirement was not met.
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) surged more than 19%. The company recently confirmed that there were no significant adverse changes in the development of its core products
Shengnuo Pharmaceutical-B (02257) surged more than 19% in the intraday period. As of press release, it rose 17.31% to HK$14.64, with a turnover of HK$43.540,800.
Changes in Hong Kong stocks | Shengnuo Pharmaceutical-B (02257) rebounded more than 10% and plummeted 33% in the previous 2 trading days. The company said the management team is still confident in the Group's long-term development prospects
Shengnuo Pharmaceutical-B (02257) rebounded more than 10%. Previously, it plummeted 33% for 2 consecutive trading days to hit a new low since listing. As of press release, it had risen 10.50% to HK$14.10, with a turnover of HK$4.01 million.
Analysis
Price Target
No Data
